<DOC>
	<DOCNO>NCT01281592</DOCNO>
	<brief_summary>This open-label , phase 1 study determine maximum tolerate dose ( MTD ) appropriate target dose MTD reach identify recommended phase 2 dose LOR-253 HCl patient advance metastatic solid tumour .</brief_summary>
	<brief_title>A Study LOR-253 HCl Patients With Advanced Metastatic Solid Tumours</brief_title>
	<detailed_description />
	<criteria>1 . Male female 18 year age old . 2 . Histologically confirm diagnosis solid tumour effective therapy available unresponsive conventional therapy . 3 . Meet laboratory parameter requirement study entry . 1 . Chemotherapy , radiotherapy , biologic therapy , immunotherapy investigational drug within 21 day begin study treatment LOR253 HCl . 2 . A hematologic malignancy . 3 . A history brain central nervous system metastasis . 4 . Have presence significant infection . 5 . Clinically significant autoimmune disease . 6 . Uncontrolled intercurrent illness . 7 . With iron copper overload syndrome . 8 . Pregnancy breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>